annual operating expenses:
$2.10B+$301.70M(+16.76%)Summary
- As of today (May 29, 2025), ALNY annual total operating expenses is $2.10 billion, with the most recent change of +$301.70 million (+16.76%) on December 31, 2024.
- During the last 3 years, ALNY annual operating expenses has risen by +$688.96 million (+48.77%).
- ALNY annual operating expenses is now at all-time high.
Performance
ALNY Operating expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly operating expenses:
$505.07M-$90.44M(-15.19%)Summary
- As of today (May 29, 2025), ALNY quarterly total operating expenses is $505.07 million, with the most recent change of -$90.44 million (-15.19%) on March 31, 2025.
- Over the past year, ALNY quarterly operating expenses has increased by +$33.28 million (+7.05%).
- ALNY quarterly operating expenses is now -15.19% below its all-time high of $595.51 million, reached on December 31, 2024.
Performance
ALNY quarterly operating expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Operating expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
ALNY Operating expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +16.8% | +7.0% |
| 3 y3 years | +48.8% | +55.7% |
| 5 y5 years | +85.3% | +70.4% |
ALNY Operating expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +48.8% | -15.2% | +55.7% |
| 5 y | 5-year | at high | +85.3% | -15.2% | +78.5% |
| alltime | all time | at high | >+9999.0% | -15.2% | >+9999.0% |
ALNY Operating expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $505.07M(-15.2%) |
| Dec 2024 | $2.10B(+16.8%) | $595.51M(+21.1%) |
| Sep 2024 | - | $491.92M(-9.3%) |
| Jun 2024 | - | $542.54M(+15.0%) |
| Mar 2024 | - | $471.79M(+0.3%) |
| Dec 2023 | $1.80B(+8.9%) | $470.26M(+4.0%) |
| Sep 2023 | - | $452.35M(-2.3%) |
| Jun 2023 | - | $463.21M(+11.8%) |
| Mar 2023 | - | $414.23M(-12.3%) |
| Dec 2022 | $1.65B(+17.0%) | $472.38M(-1.8%) |
| Sep 2022 | - | $481.23M(+28.1%) |
| Jun 2022 | - | $375.70M(+15.8%) |
| Mar 2022 | - | $324.36M(-21.9%) |
| Dec 2021 | $1.41B(+13.6%) | $415.43M(+23.4%) |
| Sep 2021 | - | $336.65M(+2.6%) |
| Jun 2021 | - | $327.96M(-1.4%) |
| Mar 2021 | - | $332.76M(-0.6%) |
| Dec 2020 | $1.24B(+9.6%) | $334.76M(+1.7%) |
| Sep 2020 | - | $329.25M(+16.4%) |
| Jun 2020 | - | $282.89M(-4.5%) |
| Mar 2020 | - | $296.33M(-17.1%) |
| Dec 2019 | $1.13B(+27.7%) | $357.58M(+27.2%) |
| Sep 2019 | - | $281.15M(+1.6%) |
| Jun 2019 | - | $276.66M(+26.5%) |
| Mar 2019 | - | $218.74M(-8.8%) |
| Dec 2018 | $887.78M(+50.5%) | $239.72M(-6.5%) |
| Sep 2018 | - | $256.49M(+15.4%) |
| Jun 2018 | - | $222.26M(+31.3%) |
| Mar 2018 | - | $169.30M(-8.6%) |
| Dec 2017 | $590.00M(+25.1%) | $185.23M(+29.6%) |
| Sep 2017 | - | $142.90M(+4.8%) |
| Jun 2017 | - | $136.41M(+8.7%) |
| Mar 2017 | - | $125.47M(-5.6%) |
| Dec 2016 | $471.75M(+39.9%) | $132.89M(+10.4%) |
| Sep 2016 | - | $120.33M(+18.9%) |
| Jun 2016 | - | $101.16M(-13.8%) |
| Mar 2016 | - | $117.37M(+17.3%) |
| Dec 2015 | $337.11M(+43.6%) | $100.06M(+18.2%) |
| Sep 2015 | - | $84.65M(+3.7%) |
| Jun 2015 | - | $81.63M(+15.4%) |
| Mar 2015 | - | $70.76M(+1.5%) |
| Dec 2014 | $234.78M | $69.73M(+24.1%) |
| Sep 2014 | - | $56.17M(-0.0%) |
| Jun 2014 | - | $56.19M(+6.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $52.68M(+30.3%) |
| Dec 2013 | $140.11M(+7.5%) | $40.44M(-1.9%) |
| Sep 2013 | - | $41.23M(+37.4%) |
| Jun 2013 | - | $30.00M(+5.5%) |
| Mar 2013 | - | $28.45M(-10.7%) |
| Dec 2012 | $130.29M(-5.3%) | $31.85M(-8.8%) |
| Sep 2012 | - | $34.91M(+5.9%) |
| Jun 2012 | - | $32.95M(+7.7%) |
| Mar 2012 | - | $30.59M(-10.1%) |
| Dec 2011 | $137.57M(-4.3%) | $34.04M(+2.4%) |
| Sep 2011 | - | $33.23M(-1.5%) |
| Jun 2011 | - | $33.73M(-7.8%) |
| Mar 2011 | - | $36.57M(+9.9%) |
| Dec 2010 | $143.78M(-3.3%) | $33.27M(-8.6%) |
| Sep 2010 | - | $36.40M(-4.8%) |
| Jun 2010 | - | $38.24M(+6.6%) |
| Mar 2010 | - | $35.87M(+3.4%) |
| Dec 2009 | $148.64M(+19.9%) | $34.70M(+2.3%) |
| Sep 2009 | - | $33.90M(-27.9%) |
| Jun 2009 | - | $47.01M(+42.3%) |
| Mar 2009 | - | $33.04M(+2.5%) |
| Dec 2008 | $124.00M(-13.9%) | $32.22M(+11.2%) |
| Sep 2008 | - | $28.97M(-21.0%) |
| Jun 2008 | - | $36.66M(+40.2%) |
| Mar 2008 | - | $26.15M(+23.8%) |
| Dec 2007 | $144.07M(+116.9%) | $21.12M(-68.8%) |
| Sep 2007 | - | $67.65M(+180.9%) |
| Jun 2007 | - | $24.09M(-22.8%) |
| Mar 2007 | - | $31.21M(+83.9%) |
| Dec 2006 | $66.43M(+35.1%) | $16.97M(+0.9%) |
| Sep 2006 | - | $16.82M(-1.8%) |
| Jun 2006 | - | $17.13M(+10.4%) |
| Mar 2006 | - | $15.51M(-5.8%) |
| Dec 2005 | $49.19M(+34.6%) | $16.47M(+36.3%) |
| Sep 2005 | - | $12.08M(-1.9%) |
| Jun 2005 | - | $12.31M(+47.9%) |
| Mar 2005 | - | $8.32M(+1.8%) |
| Dec 2004 | $36.54M(+77.2%) | $8.18M(+4.9%) |
| Sep 2004 | - | $7.79M(+9.7%) |
| Jun 2004 | - | $7.11M(-47.2%) |
| Mar 2004 | - | $13.47M(+654.8%) |
| Dec 2003 | $20.62M(+388.5%) | - |
| Jun 2003 | - | $1.78M(+40.9%) |
| Mar 2003 | - | $1.27M |
| Dec 2002 | $4.22M | - |
FAQ
- What is Alnylam Pharmaceuticals annual total operating expenses?
- What is the all time high annual operating expenses for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual operating expenses year-on-year change?
- What is Alnylam Pharmaceuticals quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly operating expenses year-on-year change?
What is Alnylam Pharmaceuticals annual total operating expenses?
The current annual operating expenses of ALNY is $2.10B
What is the all time high annual operating expenses for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual total operating expenses is $2.10B
What is Alnylam Pharmaceuticals annual operating expenses year-on-year change?
Over the past year, ALNY annual total operating expenses has changed by +$301.70M (+16.76%)
What is Alnylam Pharmaceuticals quarterly total operating expenses?
The current quarterly operating expenses of ALNY is $505.07M
What is the all time high quarterly operating expenses for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly total operating expenses is $595.51M
What is Alnylam Pharmaceuticals quarterly operating expenses year-on-year change?
Over the past year, ALNY quarterly total operating expenses has changed by +$33.28M (+7.05%)